



**CERTIFICATE OF MAILING**

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail under 37 C.F.R. 1.8 on the date indicated below and is addressed to: **MAIL STOP: AMENDMENT**; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
Date of Deposit: September 12, 2006

*Alex Grant*  
Alex Grant

Attorney Docket No. 13403.1004  
PATENT APPLICATION

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: **Petra SCHROTZ-KING, Janne SKAARUP CRAWFORD, Pia NYBORG NIELSEN, and Tatyana A. PROKHOROVA**

Application No. : 10/595,909

Group Art Unit: UNASSIGNED

Filed : May 18, 2006

For : **SURFACE-LOCATED CAMPYLOBACTER JEJUNI POLYPEPTIDES**

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

**MAIL STOP: AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir or Madam:

Transmitted herewith for filing is the following:

1. Information Disclosure Statement;
2. PTO Form /SB/08 (Substitute for form 1449A/PTO) w/attached 18 references;
3. Return-receipt postcard.

The Commissioner is hereby authorized to charge any additional fees, which may be required in connection with the filing of these documents, or credit any overpayment, to Deposit Account No. 19-3555. This sheet is submitted in duplicate.


Respectfully submitted,

*Janet Sleath*  
Janet Sleath  
Registration No.: 37,007

Date: September 12, 2006

SPECKMAN LAW GROUP PLLC

**20601**






**CERTIFICATE OF MAILING**

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail under 37 C.F.R. 1.8 on the date indicated below and is addressed to: **MAIL STOP: AMENDMENT**; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: September 12, 2006

  
Alex Grant

Attorney Docket No. 13403.1004  
**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the application of In re: **Petra SCHROTZ-KING, Janne SKAARUP CRAWFORD, Pia NYBORG NIELSEN, and Tatyana A. PROKHOROVA**

Application No. : 10/595,909                      Group Art Unit: UNASSIGNED  
Filed : May 18, 2006  
For : **SURFACE-LOCATED CAMPYLOBACTER JEJUNI POLYPEPTIDES**

**INFORMATION DISCLOSURE STATEMENT**

**MAIL STOP: AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The attached form PTO/SB/08 identifies one (1) U.S. patent reference, two (2) U.S. patent application publication references, three (3) International patent references, one (1) foreign patent reference and fourteen (14) literature references. The copy requirement pursuant to 37 CFR 1.98 has been waived and therefore copies of cited U.S. patents and patent applications are not submitted with this Information Disclosure Statement. Copies of all other cited references are enclosed herewith for the Examiner's convenience.

The documents listed on the accompanying form PTO/SB/08 are cited in compliance with the provisions of 37 C.F.R §§ 1.56, 1.97 and 1.98, as amended. Applicant does not concede that the references are "prior art" under 35 U.S.C. §102 or §103, and specifically reserves the right to antedate such materials, as by a showing under 37 C.F.R. § 1.131 or otherwise.

This Information Disclosure Statement is being filed prior to receipt of any substantive Office Action, and no fee or certification is therefore required.

Respectfully submitted,

  
Janet Sleath  
Registration No. 37,007

Date: September 12, 2006

**SPECKMAN LAW GROUP PLLC**

**20601**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10595909
Filing Date	2006-05-18
First Named Inventor	SCHROTZ-KING, Petra
Art Unit	
Examiner Name	
Attorney Docket Number	13403.1004

**U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5470958		1995-11-28	Blaser et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030072766		2003-04-17	Jacobs et al.	
	2	20020106383		2002-08-08	Mandrell et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0228889	WO		2002-04-11			<input type="checkbox"/>
	2	2296869	CA		2001-07-24			<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10595909
Filing Date	2006-05-18
First Named Inventor	SCHROTZ-KING, Petra
Art Unit	
Examiner Name	
Attorney Docket Number	13403.1004

3	0100837	WO		2001-01-04			<input type="checkbox"/>
4	0224729	WO		2002-03-28			<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Genes to genetic immunization: Identification of bacterial vaccine candidates, ALLAN et al., Elsevier, Methods 31 (2003) pp. 193-198	<input type="checkbox"/>
	2	Protection against campylobacter infection and vaccine development, SCOTT et al., American Society for Microbiology, 2000, pp. 303-319	<input type="checkbox"/>
	3	Interactions between Campylobacter jejuni and Lipids, SZYMANSKI et al., Infection and Immunity, Vol. 64, No. 9, Sept. 1996, pp 3467-3474	<input type="checkbox"/>
	4	Localization of surface immunogenic protein on Group B streptococcus, RIOUX et al., Infection and Immunity, Vol. 69, No. 8, Aug. 2001, pp. 5162-5165	<input type="checkbox"/>
	5	Animal models of campylobacter infection, YOUNG et al., American Society for Microbiology, 2000, pp. 287-301	<input type="checkbox"/>
	6	Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection, WIZEMANN et al., Infection and Immunity, Vol. 69, No. 3, Mar. 2001, pp. 1593-1598	<input type="checkbox"/>
	7	A proteomic view on genome-based signal peptide predictions, ANTELMANN et al., Genome Research, 11:1484-1502, 2001	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10595909
Filing Date	2006-05-18
First Named Inventor	SCHROTZ-KING, Petra
Art Unit	
Examiner Name	
Attorney Docket Number	13403.1004

8	Proteomics of protein secretion by bacillus subtilis: separating the "secrets" of the secretome, TJALSMA et al., Microbiology and Molecular Biology Reviews, Vol. 68, No. 2, June 2004, pp. 207-233	<input type="checkbox"/>
9	The genome sequence of the food-borne pathogen campylobacter jejuni reveals hypervariable sequences, PARKHILL et al., Nature, Vol. 403, No. 10, Feb. 2000, pp. 665-668	<input type="checkbox"/>
10	EMBL, Accession No. ABU26391, WANG et al., 19 June 2003	<input type="checkbox"/>
11	EMBL, Accession No. Q9PJ34, PARKHILL et al., 01 Oct. 2000	<input type="checkbox"/>
12	EMBL, Accession No. Q9PM33, PARKHILL et al., 01 Oct. 2000	<input type="checkbox"/>
13	EMBL, Accession No. Q9PNS2, PARKHILL et al., 01 Oct. 2000	<input type="checkbox"/>
14	EMBL, Accession No. Q9P185, ZHANG et al., 01 Oct. 2000	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10595909
Filing Date	2006-05-18
First Named Inventor	SCHROTZ-KING, Petra
Art Unit	
Examiner Name	
Attorney Docket Number	13403.1004

## CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	<i>Janet Sleath</i>	Date (YYYY-MM-DD)	2006-09-12
Name/Print	Janet Sleath	Registration Number	37,007

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.